Related references
Note: Only part of the references are listed.The Immune Response and the Pathogenesis of Idiopathic Inflammatory Myositis: a Critical Review
Angela Ceribelli et al.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2017)
Prevalence and clinical characteristics of adult polymyositis and dermatomyositis; data from a large and unselected Norwegian cohort
Cecilie Dobloug et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients
Rohit Aggarwal et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Targeting the Apo2L/TRAIL system for the therapy of autoimmune diseases and cancer
Luis Martinez-Lostao et al.
BIOCHEMICAL PHARMACOLOGY (2012)
Elevated serum TRAIL levels in scleroderma patients and its possible association with pulmonary involvement
Noha A. Azab et al.
CLINICAL RHEUMATOLOGY (2012)
The Role of TRAIL in Mediating Autophagy in Myositis Skeletal Muscle A Potential Nonimmune Mechanism of Muscle Damage
Heather M. Alger et al.
ARTHRITIS AND RHEUMATISM (2011)
Clinical characteristics and favorable long-term outcomes for patients with idiopathic inflammatory myopathies: a retrospective single center study in China
Xiao Ming Shu et al.
BMC NEUROLOGY (2011)
Deciphering the Clinical Presentations, Pathogenesis, and Treatment of the Idiopathic Inflammatory Myopathies
Lisa G. Rider et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Baseline Serum Concentrations of TRAIL in Early Rheumatoid Arthritis: Relationship with Response to Disease-modifying Antirheumatic Drugs
Paola Secchiero et al.
JOURNAL OF RHEUMATOLOGY (2010)
Apoptosis in the skeletal muscle of untreated children with juvenile dermatomyositis: Impact of duration of untreated disease
Yongdong Zhao et al.
CLINICAL IMMUNOLOGY (2007)
Novel aspects on the contribution of T cells and dendritic cells in the pathogenesis of myositis
G. Chevrel et al.
AUTOIMMUNITY (2006)
Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus
MN Lub-de Hooge et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy
L Casciola-Rosen et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Death to the bad guys: Targeting cancer via Apo2L/TRAIL
S Bouralexis et al.
APOPTOSIS (2005)
Induction of costimulation of human CD4 T cells by tumor necrosis factor-related apoptosis-inducing ligand - Possible role in T cell activation in systemic lupus erythematosus
HF Tsai et al.
ARTHRITIS AND RHEUMATISM (2004)
International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease
DA Isenberg et al.
RHEUMATOLOGY (2004)
TRAIL and apoptosis induction by TNF-family death receptors
SL Wang et al.
ONCOGENE (2003)
Polymyositis and dermatomyositis
MC Dalakas et al.
LANCET (2003)
Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy
A Almasan et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2003)
Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL-/- mice
SE Lamhamedi-Cherradi et al.
NATURE IMMUNOLOGY (2003)
Apo2L/TRAIL and its death and decoy receptors
HN LeBlanc et al.
CELL DEATH AND DIFFERENTIATION (2003)
Share Paper
